Physician profile
Bruce Greenfield
NPI 1902805724
$630.55
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $40.41 · 2021: $66.11 · 2022: $55.92 · 2023: $21.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $136.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.54 | 2019 | |
| Genentech USA, INC. | $100.00 | 2019 | |
| Janssen Biotech, INC. | $58.42 | 2019-2023 | Darzalex, Imbruvica |
| Lilly USA, LLC | $47.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.10 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.70 | 2021 | |
| Gilead Sciences, INC. | $26.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.82 | 2022 | |
| Portola Pharmaceuticals, LLC | $16.38 | 2019 | |
| Seagen INC. | $14.25 | 2020 | |
| Foundation Medicine, INC. | $13.58 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Greenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.